benzyl 2-amino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside | 210645-19-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: benzyl 2-amino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside
• 英文别名: benzyl 2-amino-3,4,6-tri-O-benzyl-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-alpha-D-glucopyranoside；N-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-amino-4,5-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]oxy-2-phenylmethoxy-6-(phenylmethoxymethyl)-4-prop-2-enoxyoxan-3-yl]acetamide
• CAS: 210645-19-5
• 化学式: C₅₂H₆₀N₂O₁₀
• 分子量: 873.056
• InChiKey: RZSHEPNITIQIJS-OMQMQTTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  64
• 可旋转键数：
  23
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  benzyl 2-amino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside 在 吡啶 、 4-二甲氨基吡啶 、 ruthenium trichloride 、 sodium periodate 作用下， 以 甲醇 、 四氯化碳 、 乙醚 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 18.0h， 生成 benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-[(2,2,2-trichloroethoxy)carbonyl]-amino-β-D-glucopyranosyl-(1→4)-2-acetamido-6-O-benzyl-2-deoxy-3-O-(methoxy-carbonyl)methyl-α-D-glucopyranoside
  参考文献：
  名称：

  Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo

  摘要：

  Fatty acyl analogues of muramyldipeptide (MDP) (abbreviated N-L18 norAbuGMDP, N-B30 norAbuGMDP, norAbuMDP-Lys(L18), norAbuMDP-Lys(B30), norAbuGMDP-Lys(L18), norAbuGMDP-Lys(B30), B30 norAbuMDP, L18 norAbuMDP) are designed and synthesized comprising the normuramyl-L-alpha-aminobutanoyl (norAbu) structural moiety. All new analogues show depressed pyrogenicity in both free (micellar) state and in liposomal formulations when tested in rabbits in vivo (sc and iv application). New analogues are also shown to be selective activators of NOD2 and NLRP3 (inflammasome) in vitro but not NOD1. Potencies of NOD2 and NLRP3 stimulation are found comparable with free MDP and other positive controls. Analogues are also demonstrated to be effective in stimulating cellular proliferation when the sera from mice are injected sc with individual liposome-loaded analogues, causing proliferation of bone marrow-derived GM-progenitors cells. Importantly, vaccination nanoparticles prepared from metallochelation liposomes, His-tagged antigen rOspA from Borrelia burgdorferi, and lipophilic analogue norAbuMDP-Lys(B30) as adjuvant, are shown to provoke OspA-specific antibody responses with a strong Th1-bias (dominance of IgG2a response). In contrast, the adjuvant effects of Alum or parent MDP show a strong Th2-bias (dominance of IgG1 response).

  DOI：

  10.1021/acs.jmedchem.7b00593
• 作为产物：
  描述：

  2-脱氧-2-苯二酰亚胺-1,3,4,6-四-氧-乙酰-β-D-吡喃葡萄糖 在 sodium tetrahydroborate 、 4 A molecular sieve 、 水 、 sodium methylate 、 四氯化钛 、 sodium hydride 、 溶剂黄146 、 三氟甲烷磺酸甲酯 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 82.0h， 生成 benzyl 2-amino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside
  参考文献：
  名称：

  New Effective Synthesis of (N-Acetyl- and N-Stearoyl-2-amino-2-deoxy-β-D-glucopyranosyl)-(1→4)-N-acetylnormuramoyl-L-2-aminobutanoyl-D-isoglutamine, Analogs of GMDP with Immunopotentiating Activity

  摘要：

  通过对乙酰氨基-3-O-丙烯基-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（7）的缩合反应，利用硫酸银盐催化的硫醚苷5和硫醚苷溴化物6在甲基三氟甲烷和溴化糖基6的存在下作为糖基供体，得到苄基-2-乙酰氨基-3-O-丙烯基-6-O-苄基-4-O-(3,4,6-三-O-苄基-2-去氧-2-邻苯二甲酰基-β-D-葡萄糖吡喃苷)-2-去氧-α-D-葡萄糖吡喃苷（8）。将其还原去邻苯二甲酰基，使用NaBH₄/醋酸作用得到苄基-2-乙酰氨基-3-O-丙烯基-4-O-(2-氨基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（11）。化合物11被N-酰化，得到苄基-2-乙酰氨基-4-O-(2-酰胺基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-3-O-丙烯基-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（12a）或（12b）。这些化合物被转化为相应的苄基-2-乙酰氨基-4-O-(2-酰胺基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-6-O-苄基-3-O-羧甲基-2-去氧-α-D-葡萄糖吡喃苷，通过与H-L-Abu-D-isoGln(OBzl)缩合，接着氢解保护性苄基基团，得到糖肽16a和16b。描述了化合物8通过烷基保护基的内分子O→N迁移，随后与叠氮或叠氮醋酸盐反应还原为丙基残基，得到苄基-2-乙酰氨基-4-O-(3,4,6-三-O-苄基-2-去氧-2-丙基氨基-β-D-葡萄糖吡喃苷)-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（9）。

  DOI：

  10.1135/cccc19980577

文献信息

• Normuramyl glycopeptide compounds
  申请人：Hipler Karsten

  公开号：US08653049B2

  公开（公告）日：2014-02-18

  The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.

  本发明提供了一种化合物（可作为佐剂），其化学式为I或II式，其中R1、R4、R5、R6和R7各自独立地选自氢、乙酰基、烃基、脂质基团和脂肪酰基团；R2为羟基、烃基、脂质基团、脂肪酰基团或者是氨基烃基团，该氨基烃基团可选择性地被氢、脂质基团或脂肪酰基团取代；R3和R8各自独立地选自乙酰基、烃基、脂质基团和脂肪酰基团；X为肽链。上述诺莫拉姆基糖肽化合物可以位于脂质体和胶束中，并可以作为免疫调节剂与所需的抗原（或DNA编码抗原）一起在（例如DNA）疫苗中发挥作用。
• COMPOUND
  申请人：Hipler Karsten

  公开号：US20110002983A1

  公开（公告）日：2011-01-06

  The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R 1 R 4 R 5 R 6 and R 7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R 2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R 3 and R 8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.

  本发明提供了一种化合物（可以作为佐剂），其化学式为I或II式，其中R1R4R5R6和R7各自独立地选择氢、乙酰、烃基、脂质基团和脂肪酰基团；R2为羟基、烃基、脂质基团、脂肪酰基团或者是氨基烃基，该氨基烃基可以选择性地取代烃基、脂质基团或脂肪酰基团；R3和R8各自独立地选择乙酰、烃基、脂质基团和脂肪酰基团；X为肽链。上述诺莫拉葡肽化合物可以位于脂质体和胶束中，并且可以与所需的抗原（或DNA编码抗原）一起在（例如DNA）疫苗中作为免疫调节剂发挥作用。
• New Effective Synthesis of (N-Acetyl- and N-Stearoyl-2-amino-2-deoxy-β-D-glucopyranosyl)-(1→4)-N-acetylnormuramoyl-L-2-aminobutanoyl-D-isoglutamine, Analogs of GMDP with Immunopotentiating Activity
  作者：Miroslav Ledvina、Daniel Zyka、Jan Ježek、Tomáš Trnka、David Šaman

  DOI：10.1135/cccc19980577

  日期：——

  Ethyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (5), prepared by benzylation of ethyl 2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (4), was transformed by reaction with bromine into 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl bromide (6). Thioglycoside 5 in the presence of methyl triflate and glycosylbromide 6 in the presence of silver triflate were used as glycosyl donors for condensation with benzyl 2-acetamido-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside (7), to give benzyl 2-acetamido-3-O-allyl-6-O-benzyl-4-O-(3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-2-deoxy-α-D-glucopyranoside (8). Its reductive dephthaloylation with NaBH₄/AcOH afforded benzyl 2-acetamido-3-O-allyl-4-O-(2-amino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl)- 6-O-benzyl-2-deoxy-α-D-glucopyranoside (11). Compound 11 was N-acylated to give benzyl 2-acetamido-4-O-(2-acylamino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl)-3-O-allyl-6-O-benzyl-2-deoxy-α-D-glucopyranosides (12a) or (12b). These compounds were converted into corresponding benzyl 2-acetamido-4-O-(2-acylamino-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl)-6-O-benzyl-3-O-carboxymethyl-2-deoxy-α-D-glucopyranosides which, by condensation with H-L-Abu-D-isoGln(OBzl) followed by hydrogenolysis of protective benzyl groups, furnished glycopeptides 16a and 16b. Intramolecular O→N migration of the allyl protecting group followed by its reduction to the propyl residue by reaction of compound 8 with hydrazine or hydrazinium acetate, to give benzyl 2-acetamido-4-O-(3,4,6-tri-O-benzyl-2-deoxy-2-propylamino-β-D-glucopyranosyl)-6-O-benzyl-2-deoxy-α-D-glucopyranoside (9), is also described.

  通过对乙酰氨基-3-O-丙烯基-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（7）的缩合反应，利用硫酸银盐催化的硫醚苷5和硫醚苷溴化物6在甲基三氟甲烷和溴化糖基6的存在下作为糖基供体，得到苄基-2-乙酰氨基-3-O-丙烯基-6-O-苄基-4-O-(3,4,6-三-O-苄基-2-去氧-2-邻苯二甲酰基-β-D-葡萄糖吡喃苷)-2-去氧-α-D-葡萄糖吡喃苷（8）。将其还原去邻苯二甲酰基，使用NaBH₄/醋酸作用得到苄基-2-乙酰氨基-3-O-丙烯基-4-O-(2-氨基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（11）。化合物11被N-酰化，得到苄基-2-乙酰氨基-4-O-(2-酰胺基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-3-O-丙烯基-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（12a）或（12b）。这些化合物被转化为相应的苄基-2-乙酰氨基-4-O-(2-酰胺基-3,4,6-三-O-苄基-2-去氧-β-D-葡萄糖吡喃苷)-6-O-苄基-3-O-羧甲基-2-去氧-α-D-葡萄糖吡喃苷，通过与H-L-Abu-D-isoGln(OBzl)缩合，接着氢解保护性苄基基团，得到糖肽16a和16b。描述了化合物8通过烷基保护基的内分子O→N迁移，随后与叠氮或叠氮醋酸盐反应还原为丙基残基，得到苄基-2-乙酰氨基-4-O-(3,4,6-三-O-苄基-2-去氧-2-丙基氨基-β-D-葡萄糖吡喃苷)-6-O-苄基-2-去氧-α-D-葡萄糖吡喃苷（9）。
• Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo
  作者：Roman Effenberg、Pavlína Turánek Knötigová、Daniel Zyka、Hana Čelechovská、Josef Mašek、Eliška Bartheldyová、František Hubatka、Štěpán Koudelka、Róbert Lukáč、Anna Kovalová、David Šaman、Michal Křupka、Lucia Barkocziova、Petr Kosztyu、Marek Šebela、Ladislav Drož、Michal Hučko、Mária Kanásová、Andrew D. Miller、Milan Raška、Miroslav Ledvina、Jaroslav Turánek

  DOI：10.1021/acs.jmedchem.7b00593

  日期：2017.9.28

  Fatty acyl analogues of muramyldipeptide (MDP) (abbreviated N-L18 norAbuGMDP, N-B30 norAbuGMDP, norAbuMDP-Lys(L18), norAbuMDP-Lys(B30), norAbuGMDP-Lys(L18), norAbuGMDP-Lys(B30), B30 norAbuMDP, L18 norAbuMDP) are designed and synthesized comprising the normuramyl-L-alpha-aminobutanoyl (norAbu) structural moiety. All new analogues show depressed pyrogenicity in both free (micellar) state and in liposomal formulations when tested in rabbits in vivo (sc and iv application). New analogues are also shown to be selective activators of NOD2 and NLRP3 (inflammasome) in vitro but not NOD1. Potencies of NOD2 and NLRP3 stimulation are found comparable with free MDP and other positive controls. Analogues are also demonstrated to be effective in stimulating cellular proliferation when the sera from mice are injected sc with individual liposome-loaded analogues, causing proliferation of bone marrow-derived GM-progenitors cells. Importantly, vaccination nanoparticles prepared from metallochelation liposomes, His-tagged antigen rOspA from Borrelia burgdorferi, and lipophilic analogue norAbuMDP-Lys(B30) as adjuvant, are shown to provoke OspA-specific antibody responses with a strong Th1-bias (dominance of IgG2a response). In contrast, the adjuvant effects of Alum or parent MDP show a strong Th2-bias (dominance of IgG1 response).